Graft Vs Host Disease clinical trials

Explore recruiting graft vs host disease clinical trials.

Recruiting graft vs host disease studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Graft Vs Host Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicenter, open-label, randomized, phase II clinical trial comparing safety and durable overall response rate (DOR) at 56 days in patients with steroid resistant severe acute GvHD after allogeneic hematopoietic stem cell transplantation treated with decidua stromal cells (DSC) or best available treatment (BAT)

Sweden, Norway, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Graft vs Host Disease Prophylaxis in unrelated donor transplantation: a randomized clinical trial comparing PTCY vs ATG

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Safety, Tolerability and Feasibility of Treatment with GP120-activated Regulatory T cells (ATreg) Early After Haematopoietic Stem Cell Transplantation (HSCT) to Reduce the Incidence and Severity of Acute Graft vs Host Disease (GvHD)

Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Poland, Czechia, Spain, Hungary, Italy, France +1 more

Therapeutic use (Phase IV) EU CTIS Study details

Graft Vs Host Disease trials by city

Graft Vs Host Disease clinical trials

Recruiting graft vs host disease studies right now

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)

Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

Repetitive Transcranial Magnetic Stimulation, a Form of Non-invasive Brain Stimulation, as a Possible Treatment for Post-stroke Fatigue.

Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy

PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control Therapy

A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD.

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Also recruiting in Europe

Graft vs Host Disease Prophylaxis in unrelated donor transplantation: a randomized clinical trial comparing PTCY vs ATG

Safety, Tolerability and Feasibility of Treatment with GP120-activated Regulatory T cells (ATreg) Early After Haematopoietic Stem Cell Transplantation (HSCT) to Reduce the Incidence and Severity of Acute Graft vs Host Disease (GvHD)

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Graft Vs Host Disease trials by city

Other conditions